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Abstract
Background: The association between disease markers and health status (HS) overtime is unclear. The aim of this
study was to verify the predictors of HS at baseline and after three years in Chronic Obstructive Pulmonary Disease
(COPD) patients.
Methods: Ninety-five consecutive COPD patients (66% male, age = 67 ± 9 y, FEV1 = 58 ± 23%) underwent the
following evaluations at baseline and after three years: body composition, pulse oximetry (SpO2), six-minute walk
distance (6MWD), Modified edical Research Council dyspnea scale (MMRC) and Saint George’s Respiratory
Questionnaire (SGRQ). The Charlson comorbidity index and BODE index were calculated. COPD exacerbations
during the follow-up were evaluated. At baseline, age, gender, smoking, SpO2, BODE index or its components (BMI,
MMRC, FEV1 and 6MWD), and Charlson index were included in a multiple linear regression analysis with the
baseline SGRQ total score as the dependent variable. After three years, we included the final values of the variables
plus the number of exacerbations and the final SGRQ total score as the dependent variable.
Results: SGRQ total score (42 ± 19% vs 44 ± 19%; p = 0.041) and activity domain (52 ± 21% vs 60 ± 22%; p <
0.001) deteriorated during follow-up. At baseline, BODE index was selected as a predictor of SGRQ total score (R2 =
0.46; p < 0.001); after three years, BODE index and age were the predictors (R2 = 0.49; p < 0.001). When the BODE
index was replaced by its variables, MMRC was selected as the only variable associated with the SGRQ total score
(R2 = 0.58; p < 0.001). After three years, MMRC, FEV1 and number of exacerbations were selected as predictors of
SGRQ total score (R2 = 0.63; p < 0.001).
Conclusion: HS deteriorated significantly over the three-year period and the predictors of HS do not change over
time. BODE index and dyspnea were predictors at baseline and after three years. Exacerbation was also a predictor
of HS after three years.
Trial Registration: ClinicalTrials.gov: NCT00605540
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Introduction
Chronic obstructive pulmonary disease (COPD) has sig-
nificant extrapulmonary consequences that lead to
comorbidity conditions and effects on patients’ quality
of life (QoL) [1]. Jones [2] empathizes that it is impor-
tant to make a distinction between QoL and and health
status (HS) measurement, since QoL has become a cen-
tral feature of studies in COPD and its impairment
reflects the impact of disease in the patient. While HS
measurement is a standardized quantification of the
impact of the disease. The purpose of these measure-
ments is to address a wide range of effects of the dis-
ease, thus provide emotional and psychological aspects
of the illness as well as the physical; however the most* Correspondence: renataferrarifisio@gmail.com
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of their items usually concern practical aspects of distur-
bance to daily life [3].
Health status is an important measurable outcome in
patients with COPD, since it is identified as a predictor
of mortality and often worsens significantly with disease
progression [4-7]. Dyspnea perception, nutritional deple-
tion, exercise tolerance impairment, exacerbation fre-
quency, and the BODE index have been identified as
predictors of HS. However, in the best equations, these
predictors explain 25% to 46% of the HS differences
between patients with COPD [7-11]. In addition, only
two studies verified associations between modifications
of disease markers and HS and both did not include
exacerbation rate as a predictor over time [7,11]. Exacer-
bations of COPD indicate progression of the disease and
are associated with reduced health status [12]. There-
fore, we hypothesized that the rate of exacerbation may
be influential in the health status over time. Identifica-
tion of predictors of HS overtime may open a window
of opportunity to direct resources in disease manage-
ment. Thus, the aim of this study was to verify the pre-




In a prospective study were recruited one hundred and
thirty three consecutive COPD patients with mild to
very severe COPD from the outpatient clinic of a single
institution. Major inclusion criteria were clinical diagno-
sis of COPD according to criteria set out in GOLD 2009
and the Brazilian Thoracic Society (BTS) [1,13], age ≥
40 years, smoking history ≥ 10 pack-years, and a post-
bronchodilator FEV1/FVC ratio < 70%. Disease severity
was categorized according of BTS and GOLD stages tak-
ing in consideration the values of FEV1 (% predicted)
and arterial blood gases (GOLD I: FEV1 ≥ 80%; GOLD
II: 50 ≤ FEV1 < 80%; GOLD III: 30 ≤ FEV1 < 50%;
GOLD IV: FEV1 < 30% or < 50% plus chronic respira-
tory failure). The following factors were considered
grounds for exclusion: a history of asthma and/or FEV1
increased > 12% or 200 mL post-bronchodilator test,
associated restrictive disorder (tuberculosis sequelae,
interstitial fibrosis); other clinically significant concomi-
tant respiratory diseases (sleep apnea/hypopnea syn-
drome, lung cancer); noncompliance with COPD
treatment; myocardial infarction within the preceding
four months; and unstable angina or congestive heart
failure (New York Heart Association class III or IV).
Patients not considered clinically stable (i.e., with
changes in medication dose or frequency, disease
exacerbation, or hospital admissions in the preceding 6
weeks) were also excluded. All patients were optimized
in terms of standard medical therapy according to
GOLD and BTS guidelines [1,13]. Active smoking
patients received practical advice to quit smoking and
were referred to smoking cessation program. Patients
with chronic hypoxemia received a stable dose of oxy-
gen therapy over the 6 months before study enrollment.
Participants were made aware of the proposed study
procedures and freely gave written informed consent.
All procedures were approved by the Research Ethics
Committee, Botucatu Medical School University Hospi-
tal (390/2007-CEP).
Measurements
Spirometry was performed, using the KOKO Spirometer,
before and 15 minutes after the inhalation of 400 mcg
salbutamol (Ferrari KOKO Louisville, CO 80027, USA),
according to criteria set by the American Thoracic
Society [14]. FEV1 values are expressed in liters, percen-
tages of FVC, and percentages of reference values [15].
Pulse oximetry (SpO2) was assessed using a Onyx oxy-
meter (Model 9500 Oximeter; Nonin Medical Inc.; Min-
neapolis, MN, USA) while patients were breathing room
air. Body weight and height were measured. Body mass
index [BMI = weight in kg/(height in m)2] was calcu-
lated. Smoking history was obtained by patient interview
using standardized instruments at baseline and smoking
cessation by self report during patients’ contacts. A
translated version of the Saint George’s Respiratory
Questionnaire (SGRQ), validated for use in Brazil, was
utilized to evaluate patient HS [16]. Minimum clinically
important difference (MCID) was defined as a decrease
of ≥ 4% in the SGRQ domains [17]. Dyspnea was
assessed using a translated version of the Modified Med-
ical Research Council (MMRC) scale [18]. The six-min-
ute walk distance (6MWD) was performed according to
American Thoracic Society guidelines [19]. BMI/airflow
obstruction/dyspnea/exercise capacity (BODE) index
was calculated using the model described by Celli et al.
[20] BODE scores were categorized as class 1 (score: 0
to 2), class 2 (score: 3 to 4); class 3 (score: 5 to 6); and
class 4 (score: 7 to 10) [20]. Comorbid disease data were
collected from patient medical records and quantified
according to the Charlson index [21]. Patients or family,
in the case of death, were contacted by telephone every
3 months to determine the occurrence of exacerbations
or hospital admissions. During the telephone interview a
structured questionnaire was used to identify data asso-
ciated with exacerbation and/or hospitalizations. Data
were confirmed during clinic visits and by reviewing
medical records. An exacerbation was defined as an
increase in dyspnea, sputum purulence, and increased
sputum volume and classified as moderate (requiring a
visit to a doctor or the emergency department and treat-
ment with antibiotics or systemic steroids or both) or
severe type II (requiring hospital admission) [22]. Mild
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exacerbations not requiring intervention were not
included in the study.
Statistical analysis
All data were analyzed using SigmaStat 3.2 (Inc, Chi-
cago, IL, USA) and STATA 10.0 (Stata Corp, Texas,
USA). Mean ± SD or median interquartile range (25-
75%) was used depending on distribution. Paired t-test
or Wilcoxon test was performed to compare characteris-
tics at baseline to those presenting after three years. At
baseline, age, gender, smoking status, SpO2, BODE
index or its components (BMI, MMRC, FEV1 and
6MWD), and Charlson index were included in a multi-
ple linear regression analysis with the baseline SGRQ
total score as the dependent variable. This analysis was
done separately for all patients evaluated at baseline and
for those followed during three years. After three years,
we included the final values of the same variables with
the final SGRQ total score as the dependent variable. In
another model, we evaluated the influence of the num-
ber of exacerbations in the previous model. This variable
was included only in the final moment because reliable
information on exacerbations was not available at base-
line and was collected during the follow-up period. The
variables included were those known to be associated
with HS in the literature and the potential confounders
[7-11]. Age and gender at baseline and the difference
between baseline and after 3 years measurements (Δ)
for pulse oximetry (Δ SpO2), Δ Bode index, Δ Charlson
index and number of exacerbation were included in a
multiple logistic regression to evaluate the influence of
these variables on clinically significant stability/improve-
ment or worsening, defined as a change ≥ 4%, of the
SGRQ domains. We repeated the previous analyses
replacing the BODE index by its components. A p <
0.05 was defined as statistically significant.
Results
The baseline characteristics of the 133 patients (69%
men) were mean age of 65 ± 9 years and smoking expo-
sure of 53 ± 28 pack-years; 45 patients (34%) were
active smokers. Seventy-two patients were using long-
term broncodilators and 49 patients were regularly
using inhaled corticosteroid, 25 had been on stable oxy-
gen flow therapy for the last six months. No patients
were medicated with theophylline or leukotriene modi-
fiers. A total of 3 (2%) patients presented congestive
heart failure class I or II, 6 (4%) patients presented dysli-
pidemia, 9 (6%) patients presented diabetes mellitus and
42 (31%) patients presented arterial hypertension at
baseline.
Of the 133 patients initially evaluated, 38 were
excluded from the final analyses; 15 patients died and
23 dropped out. Thus, 95 patients were monitored for
three years (Figure 1). Comparisons of the excluded
patients versus those completing the study did not show
significant differences at baseline (data not shown).
At baseline, the mean age of the 95 studied patients
(66% men) was 64 ± 9 years and smoking exposure was
54 ± 28 pack-years; 32 patients (33%) were active smo-
kers, and 8 of them stopped smoking during follow-up.
The comparison of patient characteristics between base-
line and after three years is shown in Table 1 and has
been presented in a previous publication [23].
At baseline, 18% of patients were in GOLD stage I,
39% were in stage II, 19% were in stage III, and 24%
were in stage IV COPD. There was no difference in the
proportion of patients within each disease severity
between baseline and after three years (p = 0.865).
According to BODE index [20], at baseline, 57 were in
class 1, 21 in class 2 and 17 were in class 3. After three
years, there was significant different between the classes,
since 51 were in class 1, 23 in class 2, 14 in class 3 and
7 patients in class 4 (p < 0.05).
Health status showed significant worsening in the
activity domain score (52 ± 21 vs. 60 ± 22%, p < 0.001)
and SGRQ total score (42 ± 19 vs. 44 ± 19%, p = 0.041)
(Figure 2). The SGRQ total scores were significantly
higher for patients in stage IV than for patients in stages
I and II, and also for patients in stage III than for
patients in stage I and for patients in stage II than
patients in stage I. We did not identify differences
between stages II and III and stages III and IV after
three years. In the BODE classification, we found that
HS change between the classes 1 and 2, classes 1 and 3
and classes 1 and 4 after three years.
Seventy-two patients (75.8%) had at least one exacer-
bation during the study period and in these patients the
baseline SGRQ total score was significantly higher [44
(30-61)%] in those without exacerbation [27 (14-39)%, p
< 0.001].
In the multiple linear regression analysis, the BODE
index was selected as predictor of SGRQ total score at
baseline (R2 = 0.46; p < 0.001). After three years, the
BODE index and the patient age were the predictors in
the model without exacerbation (R2 = 0.49; p < 0.001)
(Table 2).When exacerbation was included, the variables
selected did not change (R2 = 0.51; p < 0.001) (data not
shown). When BODE index was replaced by its variables
(BMI, MMRC, FEV1 and 6MWD), MMRC was the pre-
dictor of SGRQ total score at baseline (R2 = 0.58; p <
0.001) and MMRC and FEV1 after three years (R
2 =
0.61; p < 0.001) (Table 3). When number of exacerba-
tions was included in the model, the predictors of HS
were MMRC, FEV1 and exacerbation (R
2 = 0.63; p <
0.001) (Table 4). At baseline, predictors of HS for 133
patients were the same shown for 95 patients followed
during three years, BODE index and the patient age
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Figure 1 Diagram of patient follow up in three-year period.
Table 1 Characteristics of COPD patients followed-up over a three-year period
Variables Initial Assessment (n = 95) Final Assessment (n = 95) p-value
FEV1 (%) 59.3 ± 23.2 58.5 ± 22.7 0.228
FEV1 (L) 1.4 ± 0.6 1.3 ± 0.5 < 0.001
FVC (%) 90.8 ± 23.8 88.9 ± 24.7 0.167
FVC (L) 2.7 ± 0.8 2.5 ± 0.8 0.004
FEV1/FVC 52.2 ± 11.7 51.3 ± 10.4 0.123
BMI (kg/m2) 25.9 ± 5.8 25.8 ± 5.6 0.382
SpO2 (%) 93.6 ± 3.1 92.0 ± 4.8 < 0.001
MMRC (score) 1.5 ± 1.0 1.9 ± 1.1 0.002
6MWD (m) 437.7 ± 85.6 412. 4 ± 100.0 0.001
Charlson index (score) 3.5 ± 1.5 3.9 ± 1.4 0.009
BODE index (score) 2.2 ± 1.8 2.6 ± 2.3 0.008
Paired t-test or Wilcoxon. Values are presented as mean ± SD or as median (25-75% interquartile range). FEV1: forced expiratory volume in the first second (% of
predicted); FVC: forced vital capacity (% of predicted); BMI: body mass index; SpO2: pulse oximetry; MMRC: Modified Medical Research Council; 6MWD: six-minute
walking distance; p < 0.05.
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(data not shown). Simple correlation analysis between
baseline and final SGRQ score and age, gender, smok-
ing, SpO2, BODE index or its components, and Charlson
index are included as additional file 1.
Fifty-one percent of the patients presented with clini-
cal worsening (≥ 4%) on SGRQ total score, and 59% of
them were in severe to very severe stages of the disease.
A total of 28% reported clinical improvement and 21%
had no clinical change on SGRQ total score. In the mul-
tiple logistic regression analysis, modification in the
BODE index was the predictor of clinically significant
worsening on SGRQ total score [OR 1.48 (95% CI 1.04-
2.09); p = 0.027] (Figure 3) and on SGRQ activity
domain [OR 1.45 (95% IC 1.04-2.03); p = 0.029]. In a
second model, when BODE index was replaced by its
variables (BMI, MMRC, FEV1 and 6MWD), Δ MMRC
was the predictor of clinically significant worsening on
SGRQ total score [OR 2.73 (95% IC 1.47-5.07); p =
0.001] (Figure 4) and on activity domain [OR 1.67 (95%
IC 1.04-2.03); p = 0.031]. Predictor variables of clinically
significant stability/improvement or worsening on
SGRQ symptom and impact domains were not
identified.
Discussion
Results of this study showed that the BODE index was a
predictor of HS at baseline and after three years. The
components of BODE index associated with HS were
Figure 2 Mean SGRQ domains at baseline and after three years. SGRQ: Saint George’s Respiratory Questionnaire; *p < 0.05.
Table 2 Multiple linear regression model to evaluate predictors for baseline total SGRQ and after three years follow-
up (n = 95)
Variables Baseline total SGRQ Coefficient (95% CI) p-value Final total SGRQ Coefficient (95% CI) p-value
Male -3.41 (-11.09, 4.27) 0.380 -0.42 (-7.59, 6.73) 0.905
Age (years) -0.52 (-1.08, 0.03) 0.063 -0.62 (-1.13, -0.10) 0, 019
Smoking status 1.68 (-5.83, 9.20) 0.658 -2.70 (-10.21, 4.75) 0.470
SpO2 (%) -0.60 (-1.72, 0.52) 0.291 -0.35 (-1.06, 0.35) 0.326
Bode index (score) 5.59 (3.73, 7.45) < 0.001 4.90 (3.41, 6.40) < 0.001
Charlson index (score) -1.54 (-4.46, 1.36) 0.294 0.29 (-2.60, 3.20) 0.840
SGRQ: SpO2: pulse oximetry; Baseline (R
2 = 0.46; p < 0.05); After three years (R2 = 0.49; p < 0.05)
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dyspnea sensation and FEV1. The rate of exacerbations
also influenced the HS overtime. Clinically significant
deterioration of HS was associated with increase in dys-
pnea perception during the follow-up. These findings
reinforce the importance of therapeutic measures to
control the dyspnea, prevent progression of airflow
obstruction and exacerbations as tools to maintain or
improve the health status of COPD patients.
We observed a significant worsening in the activity
domain and SGRQ total score during the follow-up.
Our results are consistent with those of Oga et al. [7],
who showed a deterioration of health status as indicated
by increased activity and impact domains and SGRQ
total scores after a five-year period. Besides the statisti-
cally significant deterioration of HS overtime, our results
showed that 51% of the patients presented clinically sig-
nificant worsening (≥ 4%) on SGRQ total score; 59% of
these patients presented severe to very severe disease.
Oga et al. [7] showed that the mean annual change in
the health status scores was 1.87 units/year from the
SGRQ total score and took 2.14 years to deteriorate by
a clinically significant worsening of 4 units.
We observed that the SGRQ total scores tended to be
higher in patients with more advanced disease according
to GOLD staging system; however, we did not find dif-
ferences when patients with moderate and severe disease
were compared or between patients with severe and very
severe disease. Hajiro et al. [24] also demonstrated that
patients in the worst disease stage had the worst scores
on SGRQ total score; in addition, GOLD staging of
COPD was shown to be associated with important dif-
ferences in health status between severe and moderate
disease, but not between other disease stages [25].
Cross-sectional studies showed that BODE index is bet-
ter correlated to health status as assessed by a disease-
speciﬁc index for COPD than the GOLD staging criteria
based largely on the FEV1 [26,27]. Ong et al. [26] evalu-
ated 100 patients with stable COPD and found that
important differences in health status between the high-
est classes (classes 3 and 4) of the BODE classiﬁcation
system were observed but not between lower grade con-
secutive classes. In our study, we found that HS did not
change between the classes 2, 3 e 4. Despite the small
number of patients in class 4, this finding shows that
Table 3 Multiple linear regression model to evaluate predictors for baseline total SGRQ and after three years follow-
up (n = 95)
Variables Baseline total SGRQ Coefficient (95% CI) p-value Final total SGRQ Coefficient (95% CI) p-value
Male 1.11 (-6.32, 8.56) 0.766 -1.02 (-7.67, 5.62) 0.760
Age (y) -0.51 (-1.05, 0.01) 0.059 -0.14 (-0.67, 0.37) 0.570
Smoking 5.68 (-1.55, 12.93) 0.122 1.96 (-5.46, 9.40) 0.600
SpO2 (%) -0.22 (-1.29, 0.84) 0.675 -0.27 (-0.91, 0.36) 0.395
FEV1 (%) -0.11 (-0.25, 0.25) 0.105 -0.18 (-0.32, -0.05) 0.007
6MWD (m) -0.01 (-0.05, 0.03) 0.731 0.01 (-0.02, 0.56) 0.426
BMI (kg/m2) -0.24 (-0.75, 0.23) 0.349 0.18 (-0.34, 0.72) 0.489
MMRC (score) 11.72 (8.17, 15.26) < 0.001 10.44 (7.08, 13.80) < 0.001
Charlson index -1.16 (-3.82, 1.48) 0.384 -0.39 (-3.10, 2.30) 0.770
SpO2: pulse oximetry; FEV1: forced expiratory volume in the first second (% of predicted); 6MWD: six-minute walking distance; BMI: body mass index; MMRC:
Modified Medical Research Council; Baseline (R2 = 0.58; p < 0.05); After three years (R2 = 0.61; p < 0.05).
Table 4 Multiple linear regression model to evaluate predictors for total SGRQ after three years follow-up (n = 95)
Final total SGRQ (%) Dependent variables Coefficient (95% CI) p-value
Male -0.14 (-6.69, 6.40) 0.965
Age (y) -0.16 (-0.67, 0.34) 0.525
Smoking 3.05 (-4.28, 10.39) 0.410
SpO2 (%) -0.27 (-0.89, 0.35) 0.389
FEV1 (%) -0.14 (-0.28, -0.01) 0.043
6MWD (m) 0.01 (-0.02, 0.05) 0.433
BMI (kg/m2) 0.27 (-0.26, 0.79) 0.315
MMRC (score) 9.99 (6.68, 13.30) < 0.001
Charlson index (score) -0.19 (-2.84, 2.45) 0.883
Number of exacerbations 1.29 (0.11, 2.47) 0.031
SpO2: pulse oximetry; FEV1: forced expiratory volume in the first second (% of predicted); 6MWD: six-minute walking distance; BMI: body mass index; MRC:
Modified Medical Research Council; R2 = 0.63; p < 0.05.
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the health status cannot be inferred from the BODE
index and should be systematically assessed in the indi-
vidual patient. Therefore, these studies show that there
is not linearity of differences between SGRQ values in
different stages of severity.
Our results showed that FEV1 was a predictor of HS
after a three-year period. Lin et al. [11] showed that
with the decrease of airflow limitation, SGRQ total and
SGRQ subscales were increased correspondingly at base-
line and the end of 1 year. However, in Oga et al. [7],
the changes in health status assessed by the SGRQ total
scores were weakly correlated with the changes in
FEV1%.
In our study, dyspnea was strongly associated with HS
at all times. The Transition Dyspnea Index (TDI) mea-
sures changes in dyspnea sensation from baseline over
time; however, the patient has to recall their baseline
(Baseline Dyspnea Index) in order to answer questions
regarding the TDI [28]. Therefore, we used the MMRC
scale which is a traditional instrument included in the
BODE index [20]. In multiple logistic regression, when
the BODE index was replaced by its variables, worsening
of one unit in MMRC doubled the risk of worsening of
the SGRQ total score. The association between dyspnea
and HS is known from results of previous cross-sec-
tional and longitudinal studies [7,9,29]. In a five year fol-
low-up study, annual changes of the SGRQ total score
showed correlation with changes in the dyspnea inten-
sity, assessed by MMRC [7]. In the same study, the
authors verified correlation of annual changes of SGRQ
total score with anxiety, depression scores and peak oxy-
gen uptake. However, the authors did not evaluate the
influence of the BODE index and the number of exacer-
bation in the changes of health status.
Our results showed that exacerbation rate was asso-
ciated with impairment of HS during follow-up. This
finding reinforces the impact of exacerbation in clinical
outcomes; exacerbations of COPD indicate clinical
Figure 3 Multiple logistic regression analysis to evaluate the predictors for stability/improvement or worsening (≥ 4%) on SGRQ total
score (n = 95). Δ: final assessment values-initial assessment values; SpO2: pulse oximetry; Exacerbation: number of exacerbations for patient in
the three-year period.
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instability and progression of the disease and are asso-
ciated with increased morbidity, deterioration of comor-
bidities, and reduced health status [12]. In our study,
patients who had at least one exacerbation during fol-
low-up presented with higher SGRQ scores at baseline
when compared to patients without exacerbations. Spen-
cer et al. [30] showed that baseline SGRQ scores were
significantly higher in patients who experienced an
exacerbation as compared to those without exacerba-
tions during the three-year follow up. Miravitlles et al.
[31] found that among patients with moderate COPD,
those with frequent exacerbations had a greater change
in SGRQ total score (2 units per year) than those with
infrequent exacerbations, after controlling for baseline
characteristics at 2 year follow-up. However, the number
of exacerbation variables may have limitations, since
Seemungal et al. [8] have shown that about 50% of
exacerbations are untreated, or at least not reported to
physicians.
In the multiple linear regression analysis, we verified
that the BODE index was a predictor of health status
overtime. In addition, worsening of one unit of the
BODE index has a 50% increased risk of worsening in
the SGRQ total score and activity domain. Our findings
are in accord with Lin et al. [11], who found by multiple
linear regression that the BODE index was associated
with SGRQ at baseline at the end of 1 year follow up
after adjustment for age, gender, and smoking status.
COPD is a complex multidimensional disease and the
BODE index, a multidimensional grading system, has
been shown to be a superior predictor of the risk of
death [20]. BODE index is also predictor of acute
exacerbations [32], hospitalization [33] and health status
[11]. However, it does not incorporate the exacerbation
of COPD, which is an important outcome marker.
As shown in our study, HS impairment was associated
with more than one outcome measure and may reflect
the lung and systemic effects of COPD. Therefore,
Figure 4 Multiple logistic regression analysis to evaluate the predictors for stability/improvement or worsening (≥ 4%) on SGRQ total
score (n = 95). Δ: final assessment values-initial assessment values; SpO2: pulse oximetry; FEV1: forced expiratory volume in the first second (% of
predicted); 6MWD: six-minute walking distance; BMI: body mass index; MMRC: Modified Medical Research Council; Exacerbation: number of
exacerbations for patient in the three-year period.
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predictors of HS assessments will enable clinicians to
evaluate the overall efficacy of the management of dis-
ease. Health-status as a concept of high complexity is
assessed indirectly and requires the application of spe-
cially designed questionnaires [2]. The SGRQ has been
widely used in clinical trials as an endpoint to assess the
effects of treatment and management interventions on
health status in COPD [34,35], although their use in
clinical practice is hampered since this instrument is
relatively time and resource consuming. Self-rated
health (SRH) data may be an alternative because of their
simplicity of collection and strong association with out-
come [36]; such it has been shown that SRH predicted
exacerbations and hospitalizations in patients with
COPD [37]. In additional, SHR was associated with
similar HS determinants as in present study [38-40].
However, nowadays the formal questionnaires can be
completed in computers, in several places, and the
scores can be easily obtained. We believe that both
forms are necessary to be available to attend outpatients
units with different resources.
There are some limitations in our study. We did not
include depression and anxiety evaluations. In fact, psy-
chological factors were shown to have an important
impact in health status of COPD patients [41]. The lack
of these evaluations in our study may have influenced
the results and therefore, psychological or socio-cultural
aspects should also be verified in further studies
designed to evaluate the HS over time. In addition,
patients came from the outpatient clinic of a university
hospital and; therefore, may not represent the COPD
population at large.
Conclusions
In summary, HS deteriorated significantly over the
three-year period and the predictors of HS do not
change over time. BODE index and dyspnea were pre-
dictors at baseline and after three years. Exacerbation
was also a predictor of HS after three years. These
results suggest that health status scores should be
included as part of a comprehensive assessment to eval-
uate disease progression.
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